Abbott Laboratories (NYSE:ABT) Stock Unloaded Rep. Bruce Westerman

Representative Bruce Westerman (R-Arkansas) recently sold shares of Abbott Laboratories NYSE: ABT. In a filing disclosed on May 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Abbott Laboratories stock on April 21st. The trade occurred in the Representative's "FISHER IRA" account.

Representative Bruce Westerman also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of UniCredit OTCMKTS: UNCRY on 4/21/2025.
• Sold $1,001 - $15,000 in shares of CSX NASDAQ: CSX on 4/21/2025.
• Sold $1,001 - $15,000 in shares of Siemens Aktiengesellschaft OTCMKTS: SIEGY on 4/21/2025.
• Sold $1,001 - $15,000 in shares of GSK NYSE: GSK on 4/21/2025.
• Sold $1,001 - $15,000 in shares of Charles Schwab NYSE: SCHW on 4/21/2025.
• Sold $1,001 - $15,000 in shares of The Goldman Sachs Group NYSE: GS on 4/21/2025.
• Sold $1,001 - $15,000 in shares of Eli Lilly and Company NYSE: LLY on 4/21/2025.
• Sold $15,001 - $50,000 in shares of NVIDIA NASDAQ: NVDA on 4/21/2025.
• Sold $1,001 - $15,000 in shares of Chevron NYSE: CVX on 4/21/2025.
• Sold $1,001 - $15,000 in shares of Union Pacific NYSE: UNP on 4/21/2025.

Abbott Laboratories Price Performance

Shares of NYSE ABT traded up $1.44 during midday trading on Friday, reaching $134.79. The company's stock had a trading volume of 7,128,620 shares, compared to its average volume of 6,120,941. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32. The company has a 50 day moving average price of $129.31 and a 200 day moving average price of $123.88. Abbott Laboratories has a one year low of $99.71 and a one year high of $141.23. The company has a market cap of $234.51 billion, a price-to-earnings ratio of 17.62, a price-to-earnings-growth ratio of 2.52 and a beta of 0.74.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its earnings results on Wednesday, April 16th. The healthcare product maker reported $1.09 earnings per share for the quarter, topping the consensus estimate of $1.07 by $0.02. The business had revenue of $10.36 billion for the quarter, compared to the consensus estimate of $10.38 billion. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. On average, equities research analysts expect that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, May 15th. Investors of record on Tuesday, April 15th were issued a $0.59 dividend. The ex-dividend date of this dividend was Tuesday, April 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.75%. Abbott Laboratories's payout ratio is currently 30.61%.

Analyst Ratings Changes

ABT has been the topic of several analyst reports. The Goldman Sachs Group lifted their target price on shares of Abbott Laboratories from $138.00 to $154.00 and gave the stock a "buy" rating in a research report on Tuesday, March 4th. StockNews.com downgraded shares of Abbott Laboratories from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, February 12th. Citigroup boosted their price objective on shares of Abbott Laboratories from $135.00 to $160.00 and gave the company a "buy" rating in a research report on Tuesday, March 4th. Piper Sandler reiterated an "overweight" rating and issued a $145.00 price objective (up previously from $133.00) on shares of Abbott Laboratories in a research note on Thursday, April 17th. Finally, Stifel Nicolaus upped their price objective on shares of Abbott Laboratories from $135.00 to $145.00 and gave the company a "buy" rating in a research note on Thursday, April 17th. Four investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Abbott Laboratories has an average rating of "Moderate Buy" and an average price target of $142.59.

Insider Buying and Selling

In related news, EVP Andrea F. Wainer sold 949 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $138.17, for a total transaction of $131,123.33. Following the completion of the sale, the executive vice president now owns 74,381 shares in the company, valued at $10,277,222.77. This trade represents a 1.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Sally E. Blount sold 2,600 shares of the stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $129.66, for a total transaction of $337,116.00. Following the sale, the director now owns 34,058 shares of the company's stock, valued at $4,415,960.28. This trade represents a 7.09% decrease in their position. The disclosure for this sale can be found here. Insiders sold 95,278 shares of company stock worth $12,745,859 in the last quarter. 0.46% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Abbott Laboratories

A number of hedge funds and other institutional investors have recently made changes to their positions in ABT. Redwood Park Advisors LLC bought a new position in shares of Abbott Laboratories during the 4th quarter worth about $25,000. Noble Wealth Management PBC bought a new position in shares of Abbott Laboratories during the 4th quarter worth about $26,000. NewSquare Capital LLC lifted its holdings in shares of Abbott Laboratories by 78.4% during the 4th quarter. NewSquare Capital LLC now owns 239 shares of the healthcare product maker's stock worth $27,000 after acquiring an additional 105 shares during the period. Hughes Financial Services LLC acquired a new stake in shares of Abbott Laboratories during the 1st quarter worth about $27,000. Finally, WealthTrak Capital Management LLC acquired a new stake in shares of Abbott Laboratories during the 4th quarter worth about $28,000. 75.18% of the stock is owned by institutional investors.

About Representative Westerman

Bruce Westerman (Republican Party) is a member of the U.S. House, representing Arkansas' 4th Congressional District. He assumed office on January 3, 2015. His current term ends on January 3, 2027. Westerman (Republican Party) is running for re-election to the U.S. House to represent Arkansas' 4th Congressional District. He declared candidacy for the 2026 election. Westerman earned his BSBAGE in biological and agricultural engineering from the University of Arkansas in 1990 and his MF in forestry from Yale University in 2001. His professional experience includes working as a plant engineer for Riceland Foods and an engineer/forester for Mid-South Engineering Company.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.